Clostridium difficile infection
Conditions
Interventions
Subgroup 1: Brachydia yeast powder (500mg bid) + vancomycin (125mg qid) ×14 days :None
Subgroup 2: Brachydia yeast powder (500mg bid) + metronidazole (500mg tid) ×14 days :None
Subgroup 3: Vancomycin (125mg qid) ×14 days alone :None
Subgroup 4: Metronidazole (500mg tid) ×14 days alone:None
Sponsors
Sun Yat-sen University Affiliated Sixth Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age between 18-75 years, both male and female, diagnosed with UC (refer to the 2023 Xi'an Guidelines for the Diagnosis and Treatment of Ulcerative Colitis in China); 2. CDI diagnosis: diarrhea (>=3 times/day) and positive for Clostridium difficile toxin B test; 3. Modified Mayo score of 3-12 points (mild to moderate active phase); 4. The treatment of Clostridium difficile infection is determined by the clinical physician's opinion; 5. The individual or legal guardian signs the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with tumor diseases and a survival period of less than 6 months; 2. Patients with fulminant colitis, intestinal perforation, or toxic megacolon; 3. Patients who have used probiotics or fecal microbiota transplantation within 30 days; 4. Individuals with combined immune deficiency (HIV, active tuberculosis), autoimmune diseases, or blood disorders, or those who have recently received immunosuppressive therapy; 5. Individuals with coagulation disorders or bleeding tendencies; 6. Pregnant or breastfeeding women; 7. Individuals with mental illness; 8. Those deemed unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clostridium difficile toxin B negativization rate; | — |
Countries
China
Contacts
Public ContactGao Xiang
Sun Yat-sen University Affiliated Sixth Hospital
Outcome results
None listed